Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06168409




Registration number
NCT06168409
Ethics application status
Date submitted
5/12/2023
Date registered
13/12/2023
Date last updated
24/10/2024

Titles & IDs
Public title
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Secondary ID [1] 0 0
D6970C00009
Universal Trial Number (UTN)
Trial acronym
Bax24
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Resistant Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Baxdrostat
Treatment: Drugs - Placebo

Experimental: 2 mg baxdrostat - 2 mg baxdrostat administered orally, once daily (QD).

Placebo comparator: Placebo - Placebo administered orally, once daily (QD)


Treatment: Drugs: Baxdrostat
Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:

• 2 mg per tablet.

Treatment: Drugs: Placebo
Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in ambulatory 24-hour average SBP
Timepoint [1] 0 0
At Week 12
Secondary outcome [1] 0 0
Change from baseline in ambulatory night-time average SBP
Timepoint [1] 0 0
At Week 12
Secondary outcome [2] 0 0
Change from baseline in ambulatory daytime average SBP
Timepoint [2] 0 0
At Week 12
Secondary outcome [3] 0 0
Change from baseline in seated SBP
Timepoint [3] 0 0
At Week 12
Secondary outcome [4] 0 0
Participants achieving ambulatory 24-hour average SBP of < 130 mmHg
Timepoint [4] 0 0
At Week 12
Secondary outcome [5] 0 0
Change from baseline in ambulatory 24-hour average DBP
Timepoint [5] 0 0
At Week 12
Secondary outcome [6] 0 0
Change from baseline in ambulatory night-time average DBP
Timepoint [6] 0 0
At Week 12
Secondary outcome [7] 0 0
Change from baseline in the average ambulatory daytime average DBP
Timepoint [7] 0 0
At Week 12
Secondary outcome [8] 0 0
Change from baseline on seated DBP
Timepoint [8] 0 0
At Week 12
Secondary outcome [9] 0 0
Achieving a nocturnal SBP dipping of = 10%
Timepoint [9] 0 0
At Week 12.

Eligibility
Key inclusion criteria
* Participant must be = 18 years old, at the time of signing the informed consent.
* Mean seated SBP on AOBPM of = 140 mmHg and < 170 mmHg at Screening.
* Have a stable regimen of = 3 antihypertensive medications, from different therapeutic classes (at least one should be a diuretic), at maximum tolerated dose in the judgement of the Investigator, for at least 4 weeks prior to Screening (participants who do not meet this criterion may be rescreened at the Investigator's discretion). Beta blockers used to treat other conditions (ie, migraine, HF, coronary artery disease) should not be counted as an antihypertensive medication for the purpose of qualifying for this study.
* Have eGFR = 45 mL/min/1.73 m2 at Screening.
* Serum potassium (K+) level = 3.5 and < 5.0 mmol/L at Screening, determined as per central laboratory
* Randomization Criteria: mean ambulatory SBP of = 130 mmHg at randomisation.
Minimum age
18 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Mean seated SBP on AOBPM = 170 mmHg at Screening.
* Mean seated DBP on AOBPM = 110 mmHg at Screening.
* Serum sodium level < 135 mmol/L at Screening, as per central laboratory.
* Participant has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
* New York Heart Association functional HF class IV at Screening.
* Persistent atrial fibrillation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
5/09/2025
Actual
Sample size
Target
212
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Clayton
Recruitment hospital [2] 0 0
Research Site - Perth
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Argentina
State/province [10] 0 0
Caba
Country [11] 0 0
Argentina
State/province [11] 0 0
Capital Federal
Country [12] 0 0
Argentina
State/province [12] 0 0
Lanus Este
Country [13] 0 0
Argentina
State/province [13] 0 0
San Miguel de Tucuman
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Belgium
State/province [15] 0 0
Mons
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Canada
State/province [17] 0 0
Alberta
Country [18] 0 0
Canada
State/province [18] 0 0
British Columbia
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
Czechia
State/province [21] 0 0
Brandys nad Labem
Country [22] 0 0
Czechia
State/province [22] 0 0
Broumov
Country [23] 0 0
Czechia
State/province [23] 0 0
Louny
Country [24] 0 0
Germany
State/province [24] 0 0
Bad Homburg
Country [25] 0 0
Germany
State/province [25] 0 0
Bad Oeynhausen
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Germany
State/province [27] 0 0
Elsterwerda
Country [28] 0 0
Germany
State/province [28] 0 0
Erfurt
Country [29] 0 0
Germany
State/province [29] 0 0
Frankfurt
Country [30] 0 0
Greece
State/province [30] 0 0
Athens
Country [31] 0 0
Greece
State/province [31] 0 0
Attica
Country [32] 0 0
Greece
State/province [32] 0 0
Thessaloniki
Country [33] 0 0
Hungary
State/province [33] 0 0
Budapest
Country [34] 0 0
Hungary
State/province [34] 0 0
Nyíregyháza
Country [35] 0 0
Hungary
State/province [35] 0 0
Pécs
Country [36] 0 0
Malaysia
State/province [36] 0 0
Kota Bharu
Country [37] 0 0
Malaysia
State/province [37] 0 0
Muar
Country [38] 0 0
Malaysia
State/province [38] 0 0
Sarawak Miri
Country [39] 0 0
Philippines
State/province [39] 0 0
Angeles City
Country [40] 0 0
Philippines
State/province [40] 0 0
Iloilo City
Country [41] 0 0
Poland
State/province [41] 0 0
Bialystok
Country [42] 0 0
Poland
State/province [42] 0 0
Gdansk
Country [43] 0 0
Poland
State/province [43] 0 0
Kraków
Country [44] 0 0
Poland
State/province [44] 0 0
Lodz
Country [45] 0 0
Poland
State/province [45] 0 0
Poznan
Country [46] 0 0
Poland
State/province [46] 0 0
Warszawa
Country [47] 0 0
Saudi Arabia
State/province [47] 0 0
Riyadh
Country [48] 0 0
Slovakia
State/province [48] 0 0
Brezno
Country [49] 0 0
Slovakia
State/province [49] 0 0
Kosice
Country [50] 0 0
Slovakia
State/province [50] 0 0
Svidník
Country [51] 0 0
South Africa
State/province [51] 0 0
Cape Town
Country [52] 0 0
South Africa
State/province [52] 0 0
Durban
Country [53] 0 0
Spain
State/province [53] 0 0
Barcelona
Country [54] 0 0
Spain
State/province [54] 0 0
Madrid
Country [55] 0 0
Spain
State/province [55] 0 0
Oviedo
Country [56] 0 0
Spain
State/province [56] 0 0
Santa Coloma de Gramenet
Country [57] 0 0
Spain
State/province [57] 0 0
Terrassa (Barcelona)
Country [58] 0 0
Taiwan
State/province [58] 0 0
New Taipei
Country [59] 0 0
Taiwan
State/province [59] 0 0
Taipei
Country [60] 0 0
Taiwan
State/province [60] 0 0
Taoyuan
Country [61] 0 0
Thailand
State/province [61] 0 0
Bangkok
Country [62] 0 0
Thailand
State/province [62] 0 0
Chiang Mai
Country [63] 0 0
Thailand
State/province [63] 0 0
Muang
Country [64] 0 0
Turkey
State/province [64] 0 0
Adana
Country [65] 0 0
Turkey
State/province [65] 0 0
Ankara
Country [66] 0 0
Turkey
State/province [66] 0 0
Istanbul
Country [67] 0 0
Turkey
State/province [67] 0 0
Kahramanmaras
Country [68] 0 0
Turkey
State/province [68] 0 0
Kayseri
Country [69] 0 0
Turkey
State/province [69] 0 0
Odunpazari
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Canterbury
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Corby
Country [72] 0 0
United Kingdom
State/province [72] 0 0
London
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Prescot
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Stockport
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Swindon
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Thetford
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Weston-Super-Mare
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Yate
Country [79] 0 0
Vietnam
State/province [79] 0 0
Hanoi
Country [80] 0 0
Vietnam
State/province [80] 0 0
Ho Chi Minh
Country [81] 0 0
Vietnam
State/province [81] 0 0
Hochiminh city

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP = 140 mmHg at Screening and mean ambulatory SBP = 130 mmHg at baseline, despite a stable regimen of = 3 antihypertensive agents, one of which is a diuretic).
Trial website
https://clinicaltrials.gov/study/NCT06168409
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06168409